Argo Biopharma reports 83%-96% HAE attack reductions for BW-20805
AI Summary- Argo Biopharma announced updated BW-20805 Phase II data for oral presentation at Bradykinin Symposium 2026.
- 83%, 96% and 93% were the attack-rate reductions across the three dosing groups.
- 25 participants were randomized and dosed by the June 2026 data cutoff.